


## BRAF V600E Antibody [clone V600E/1322] (V5230)

Catalog No.	Formulation	Size
V5230-100UG	0.2 mg/ml in 1X PBS with 0.1 mg/ml BSA (US sourced), 0.05% sodium azide	100 ug
V5230-20UG	0.2 mg/ml in 1X PBS with 0.1 mg/ml BSA (US sourced), 0.05% sodium azide	20 ug
V5230SAF-100UG	1 mg/ml in 1X PBS; BSA free, sodium azide free	100 ug

[Bulk quote request](#)

<b>Availability</b>	1-3 business days
<b>Species Reactivity</b>	Human
<b>Format</b>	Purified
<b>Host</b>	Mouse
<b>Clonality</b>	Monoclonal (mouse origin)
<b>Isotype</b>	Mouse IgG, kappa
<b>Clone Name</b>	V600E/1322
<b>Purity</b>	Protein A affinity
<b>UniProt</b>	P15056
<b>Localization</b>	Nucleus, Cytoplasm, Cell membrane
<b>Applications</b>	ELISA (Order BSA-free Format For Coating) :
<b>Limitations</b>	This BRAF V600E antibody is available for research use only.



SDS-PAGE analysis of purified, BSA-free BRAF V600E antibody (clone V600E/1322) as confirmation of integrity and purity.

### Description

The BRAF gene encodes a cytoplasmic serine-threonine kinase, which initiates the activation of the mitogen-activated protein kinase (MAPK) signalling pathway. The oncogenic mutations in the kinase region of BRAF gene result in

constitutive activation of the MAPK signalling pathway, leading to increased cell proliferation, resistance to apoptosis and tumor progression. The most common of all activating BRAF mutations leads to a substitution of valine (V) to glutamic acid (E) at the position 600 of the amino acid sequence. The BRAF V600E mutation is an important predictive and prognostic biomarker. The BRAF V600E mutation is detected in approximately 8% of all solid tumours, including 45% of papillary thyroid carcinomas, 40-60% of melanomas, 5-15% of colorectal adenocarcinomas, 35% of serous low grade and borderline ovarian carcinomas, 1-3% of non-small cell lung cancers, and 5-7% of cholangiocarcinomas. Furthermore, the BRAF V600E mutation is found in 100% of hairy cell leukaemia, 54% Erdheim-Chester disease, 38% of Langerhans cell histiocytoses and 60% of pleomorphic xanthoastrocytomas.

## Application Notes

Optimal dilution of the BRAF V600E antibody should be determined by the researcher.

## Immunogen

An N-terminal KLH-conjugated peptide (amino acids 596-606, Cys-GLAT(E)KSRWSG) was used as the immunogen for the BRAF V600E antibody.

## Storage

Aliquot the BRAF V600E antibody and store frozen at -20oC or colder. Avoid repeated freeze-thaw cycles.